ketoconazole has been researched along with rifampin in 164 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 20 (12.20) | 18.7374 |
| 1990's | 9 (5.49) | 18.2507 |
| 2000's | 28 (17.07) | 29.6817 |
| 2010's | 100 (60.98) | 24.3611 |
| 2020's | 7 (4.27) | 2.80 |
| Authors | Studies |
|---|---|
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Bernardino, AMR; Boechat, N; Dos Santos, MS; Faria, JV; Miguita, AGC; Vegi, PF | 1 |
| Bloomer, WD; Papadopoulou, MV; Rosenzweig, HS | 1 |
| Fu, L; Huang, H; Li, G; Li, Y; Liu, Y; Lu, H; Lu, Y; Ma, C; Sheng, L; Wang, B; Zhang, B; Zhang, D; Zhao, H | 1 |
| Delabio, LC; Dutra, JP; Hembecker, M; Kita, DH; Moure, VR; Pereira, GDS; Scheiffer, G; Valdameri, G; Zattoni, IF | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Hashizume, H; Kawasaki, M; Komatsu, M; Matsumoto, M; Sasaki, H; Shimokawa, Y; Tomishige, T; Tsubouchi, H | 1 |
| Ekins, S; Harwood, HJ; Hoover, DJ; Lawton, MP; Mankowski, DC; Treadway, JL | 1 |
| Cho, SH; Franzblau, SG; Hwang, CH; Pauli, GF; Wan, B; Warit, S | 1 |
| Artursson, P; Bergström, CA; Hoogstraate, J; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Anguiano, J; Das, BC; Ganellin, CR; Kim, S; Madhukumar, AV; Mani, S; Power, EC; Sinz, M; Zvyaga, TA | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| Chlipala, G; Krunic, A; Mo, S; Orjala, J | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Alves, AJ; Alves, AQ; Alves, EW; Carvalho, CS; de Aquino, TM; de Araújo, JM; de Faria, AR; de Lima, JG; de Melo, EJ; Góes, AJ; Liesen, AP; Lima, VT | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ghosh, I; Manoharlal, R; Prakash, O; Prasad, R; Puri, N; Sharma, M | 1 |
| Glen, RC; Lowe, R; Mitchell, JB | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Barber, J; Dawson, S; Kenna, JG; Paul, N; Stahl, S | 1 |
| Baucom, CC; Chang, TK; Lau, AJ; Rajaraman, G; Yang, G | 1 |
| Chikhalia, KH; Kumari, P; Patel, PK; Patel, RV; Rajani, DP | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Cai, G; Cho, S; Franzblau, SG; Jaki, BU; Lee, IA; McAlpine, JB; Napolitano, JG; Pauli, GF; Suh, JW; Wang, Y; Yang, SH | 1 |
| Artursson, P; Mateus, A; Matsson, P | 1 |
| Aleo, MD; Bonin, PD; Luo, Y; Potter, DM; Swiss, R; Will, Y | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Carazo, A; Drechslerová, M; Hrušková, ZR; Hyrsova, L; Kuneš, J; Nova, A; Pavek, P; Pour, M; Smutny, T; Špulák, M | 1 |
| Asiri, AM; Darshini, N; Leng, J; Mallesha, N; Marwani, HM; Qin, HL; Rakesh, KP; Shubhavathi, T; Vivek, HK; Zha, GF | 1 |
| Denning, DW; Graybill, JR; Hanson, LH; Pappagianis, D; Rinaldi, MG; Sharkey, PK; Stevens, DA; Tucker, RM | 1 |
| Gibaldi, M | 2 |
| Bhatt, KM; Okelo, GB; Sang, D | 1 |
| Alberico, G; Cotilli, G; Goitre, M; Puiatti, P; Salvai, M | 1 |
| Lucente, FE; Meiteles, LZ | 1 |
| Baciewicz, AM; Baciewicz, FA | 1 |
| Acevedo, C; De Salvo, MC; Galati, MR; García Fernández, JC; Masana, M; Mingolla, L; Negroni, R; Pilheu, JA; Rubio, MC; Yunis, AS | 1 |
| Baciewicz, AM; Bekemeyer, WB; Self, TH | 1 |
| Abruzzo, GK; Fromtling, RA; Giltinan, DM; Turnbull, TA | 1 |
| Dennis, M; Le, CT | 1 |
| Abadie-Kemmerly, S; Dalovisio, JR; Dalvisio, JR; Pankey, GA | 1 |
| Doble, N; Keal, EE; Lush, M; Rowland-Hill, C; Shaw, R; Warnock, DW | 1 |
| Bacher, J; O'Leary, T; Pizzo, PA; Thaler, M | 1 |
| Meunier, F | 1 |
| Selden, ST | 1 |
| Doble, N; Hykin, P; Keal, EE; Shaw, R | 1 |
| Craven, PC | 1 |
| Ajello, L; Padhye, AA; Shlaes, DM; Vartian, CV | 1 |
| El-On, J; Weinrauch, L | 1 |
| Engelhard, D; Marks, MI; Stutman, HR | 1 |
| Moody, MR; Morris, MJ; Schimpff, SC; Young, VM | 1 |
| Blaschke, TF; Brass, C; Defelice, R; Galgiani, JN; O'Reilly, RA; Stevens, DA | 1 |
| Corrado, ML; Cummings, M; Eng, RH; Kramer, M | 1 |
| Berman, JD; Lee, LS | 1 |
| Gerding, DN; Harris, C; Hughes, CE; Moody, JA; Peterson, LR | 1 |
| Benet, LZ; Gomez, DY; Gupta, SK; Hebert, MF; Rowland, M; Wacher, VJ; Wu, CY | 1 |
| Andres, A; Carreño, A; Cubas, A; Delgado, M; Dominguez-Gil, B; Herrero, JC; Latorre, A; Manzanares, C; Morales, E; Morales, JM; Moreno, M | 1 |
| Arold, G; Bauer, S; Brockmöller, J; Roots, I; Schmider, J | 1 |
| Bryson, H; Goggin, T; Grub, S; Jorga, K; Lüdin, E | 1 |
| Bajpai, A; Gupta, AK; Kabra, SK; Kalra, V; Samantaray, JC; Satpathy, G; Singhal, T | 1 |
| Bigler, L; Follath, F; Ha, HR; Kozlik, P; Stieger, B | 1 |
| Beijnen, JH; Huitema, AD; Jansen, M; Jansen, RL; Kerbusch, T; Mathôt, RA; van Rijswijk, RE | 1 |
| Koibuchi, N; Ozawa, Y; Taguchi, M; Takeshita, A | 1 |
| Akiyama, TE; Cheung, C; Elizondo, G; Feigenbaum, L; Gonzalez, FJ; Granvil, CP; Krausz, KW; Yu, AM | 1 |
| Hansen, KT; Hatorp, V; Thomsen, MS | 1 |
| Gundu, J; Machavaram, KK; Yamsani, MR | 2 |
| Baldes, C; Koenig, P; Kohlbacher, O; Lehr, CM; Lenhof, HP; Neumann, D | 1 |
| Marks, B; Raucy, J; Trubetskoy, O; Yueh, MF; Zielinski, T | 1 |
| Lin, JH | 1 |
| Azuma, J; Hou, XL; Kinoshita, N; Komatsu, K; Qiu, F; Takahashi, K; Tanaka, K | 1 |
| Andersen, V; Autrup, H; Eriksen, J; Guldborg Nyvold, C; Hyldahl Olesen, L; Jakobsen, P; Larsen, UL; Østergaard, M | 1 |
| Byrne, ST; Denkin, SM; Gu, P; Nuermberger, E; Zhang, Y | 1 |
| Gonzalez, FJ | 1 |
| Cheung, C; Gonzalez, FJ; Idle, JR; Krausz, KW; Ma, X; Shah, YM; Wang, T | 1 |
| Jaworska, O; Sapierzyński, R | 1 |
| Huang, JD; Kuo, SC; Lai, ML; Lim, YP | 1 |
| Cho, JY; Jang, IJ; Kim, BH; Kim, JW; Kim, TE; Shin, KH; Shin, SG; Yi, S; Yoon, SH; Yu, KS | 1 |
| Adams, LM; Apseloff, G; Blum, RA; Gainer, SD; Johnson, BM; Kirby, LC; Lebowitz, PF; Morrison, RA; Schutz, RA; Zhang, K | 1 |
| Darnell, M; Edebert, I; Ek, M; Ingelman-Sundberg, M; Neve, EP; Sivertsson, L | 1 |
| Damle, B; Fahmi, OA; Gandelman, K; Glue, P; Lian, K; Obach, RS; Zhu, T | 1 |
| Galitz, L; Grouss, K; Harrell, R; Schran, H; Sethuraman, V; Smith, T; Tanaka, C; Yin, OQ | 1 |
| Kumar, V; Lee, CM; Morgan, ET; Riley, RI | 1 |
| Croubels, S; Gadeyne, C; Gasthuys, F; Polis, I; Schauvliege, S; Van der Heyden, S | 1 |
| Blood, J; Buck, N; Kharasch, ED; Kim, T; London, A; Mach, RH; Vangveravong, S | 1 |
| Ahn, SH; Bae, MA; Choi, MK; Choi, YL; Jin, QR; Song, IS | 1 |
| Chen, X; Emm, T; Landman, RR; Lo, Y; McGee, RF; McKeever, EG; Punwani, NG; Scherle, PA; Shi, JG; Williams, WV; Yeleswaram, S | 1 |
| Bricmont, P; Mallikaarjun, S; Shoaf, SE | 1 |
| Agrawal, N; Breidinger, S; Iwamoto, M; Johnson-Levonas, A; Kraft, WK; Marsilio, S; McCrea, J; Murphy, G; Orford, K; Palcza, J; Panebianco, D; Stroh, M; Trucksis, M; Wagner, JA | 1 |
| Blode, H; Kunz, M; Mellinger, U; Parke, S; Rohde, B; Zeun, S; Zimmermann, T | 1 |
| Bae, KS; Choi, HY; Jin, SJ; Kim, MJ; Kim, YH; Lim, HS; Noh, YH; Sung, HR | 1 |
| Chiers, K; Croubels, S; Daminet, S; Ducatelle, R; Gadeyne, C; Hesta, M; Murua Escobar, H; Polis, I; Schauvliege, S; Sterenczak, K; Van der Heyden, S | 1 |
| Adda, N; Alves, K; Chandorkar, G; Garg, V; McNair, L; Smith, F; van Heeswijk, RP; Yang, Y | 1 |
| Adamson, D; Brown, K; Chen, E; Evans, TR; Hotte, S; Kollmansberger, C; Lassen, U; Meyer, T; Miller, WH; Nielsen, DL; Rafi, R; Sawyer, MB; Spicer, J | 1 |
| Cho, JY; Jang, IJ; Kim, JW; Kim, TE; Lee, MG; Lim, KS; Shin, SG; Song, IS; Yi, S; Yoon, SH; Yu, KS | 1 |
| Cutler, DL; Johnson-Levonas, AO; Kosoglou, T; Kumar, B; Schiller, JE; Statkevich, P; Xuan, F; Young, S | 1 |
| Bloch, N; Chaudhry, A; Ekins, S; Kalpana, G; Li, H; Mani, S; Mukherjee, P; Negassa, A; Redinbo, MR; Venkatesh, M | 1 |
| Chin-Hong, PV; Hickey, MD; Quan, DJ; Roberts, JP | 1 |
| Keirns, J; Kerbusch, V; Kowalski, D; Krauwinkel, W; Lee, J; Marion, A; Meijer, J; Moy, S; Roy, M; Sawamoto, T; Takusagawa, S; van Gelderen, M | 1 |
| Calcagnile, S; Henriksson, A; Kammerer, KP; Lanzarotti, C; Rossi, G; Timmer, W | 1 |
| Alley, SC; Chen, R; Cooper, M; Gopal, AK; Goy, A; Grove, LE; Han, TH; Lynch, CM; Matous, JV; O'Connor, OA; Ramchandren, R | 1 |
| Cho, JY; Choi, MH; Jang, IJ; Lim, KS; Shin, KH; Yu, KS | 1 |
| Lammintausta, R; Lehtinen, T; Pelkonen, O; Scheinin, M; Tolonen, A; Turpeinen, M; Uusitalo, J; Vuorinen, J | 1 |
| Beumer, JH; Christner, SM; Gramignoli, R; Parise, RA; Pillai, VC; Rudek, MA; Strom, SC; Venkataramanan, R | 1 |
| Buchbjerg, JK; Chen, G; Højer, AM; Lee, R; Serenko, M; Zhao, Z | 1 |
| Chen, XY; Gao, ZW; Meng, J; Zhong, DF; Zhou, X | 1 |
| Dutreix, C; Lorenzo, S; Munarini, F; Roesel, J; Wang, Y | 1 |
| Hee, KH; Lee, LS; Yao, Z | 1 |
| Malhotra, B; Oishi, M; Tomono, Y; Yamagami, H | 1 |
| Chang, JH; Cheong, J; Ly, J; Messick, K; Plise, E; Wright, M; Zhang, X | 1 |
| Chiu, YY; Ereshefsky, L; Loebel, A; Poola, N; Preskorn, SH | 1 |
| Boulton, DW; Goodenough, A; Jemal, M; Kasichayanula, S; LaCreta, F; Lee, M; Luo, WL; Rodrigues, AD; Yang, Z | 1 |
| Beumer, JH; Christner, SM; Parise, RA; Pillai, VC; Rudek, MA; Venkataramanan, R | 1 |
| Liu, Y; Palmisano, M; Wan, Y; Wu, A; Zhou, S | 1 |
| Alexander, N; Barve, A; Einolf, H; Gu, H; Hanna, I; He, H; Heimbach, T; Ke, J; Mangold, JB; Sunkara, G; Wang, L; Xia, B; Zhang, T | 1 |
| Chen, X; Gao, R; Pang, X; Zhang, Y; Zhong, D; Zhong, K | 1 |
| Bernard, A; Dirix, L; Herremans, C; Keung, C; Khokhar, NZ; Knoblauch, R; Machiels, JP; Parekh, TV; Phelps, C; Sharma, S; Staddon, A | 1 |
| Chen, Y; Girish, S; Hop, C; Jin, JY; Li, C; Lu, D; Mukadam, S; Samineni, D; Shen, BQ; Wong, H | 1 |
| Dedieu, JF; Kassalow, L; Lockhart, AC; Mita, AC; Mita, MM; Morris, JC; Rixe, O; Sarantopoulos, J; Wack, C; Wade, JL | 1 |
| Kaur, P; Sodhi, RK | 1 |
| Fraczkiewicz, G; Shi, JG; Williams, WV; Yeleswaram, S | 1 |
| Chen, J; Hu, P; Jiang, J; Liu, D; Zhao, Q; Zheng, X | 1 |
| Baroldi, P; Dressman, MA; Kramer, WG; Ogilvie, BW; Torres, R | 1 |
| Benrimoh, N; Engel, C; Holland, J; Lacy, S; Miles, D; Nguyen, L; O'Reilly, T | 1 |
| Arkenau, HT; Burris, HA; Infante, J; Jones, SF; Laille, E; Lemech, C; Liu, L; Patel, M | 1 |
| Beumer, JH; Christner, SM; Kiesel, BF; Parise, RA; Pillai, VC; Rudek, MA; Venkataramanan, R | 1 |
| Johnson, TR; Smith, BJ; Yamazaki, S | 1 |
| Boldrin, M; Georgy, A; Liang, Z; Zhai, S; Zhi, J | 1 |
| Bello, A; Brega, N; O'Gorman, M; Tan, W; Xu, H | 1 |
| Buchmann, S; de Kanter, R; Delahaye, S; Gnerre, C; Kohl, C; Segrestaa, J; Sidharta, PN; Treiber, A | 1 |
| Baluom, M; Brealey, C; Craven, K; Gillen, M; Grossbard, EB; Lau, D; Mant, T; Martin, P; Millson, D; Oliver, S; Sweeny, D | 1 |
| Barve, A; Crabbe, R; Dabovic, K; Dole, K; Grosgurin, P; Ke, J; Kovacs, SJ; Menetrey, A; Nicolas-Métral, V; Praestgaard, J; Stein, D; Sunkara, G; Zhang, J | 1 |
| Acharya, M; Bernard, A; Chien, C; De Vries, R; Jiao, J; Monbaliu, J; Stieltjes, H; Tran, N; Vaccaro, N; Yu, M | 1 |
| Cotreau, MM; Miller, J; Siebers, NM; Slichenmyer, W; Strahs, AL | 1 |
| Ahn, LY; Cho, JY; Choi, MH; Jang, IJ; Lee, J; Moon, JY; Shin, KH; Yu, KS | 1 |
| De Jong, J; de Zwart, L; Mannaert, E; Monshouwer, M; Snoeys, J; Sukbuntherng, J | 1 |
| Einolf, HJ; Rebello, S; Wang, L; Won, C; Zhou, J | 1 |
| Abbas, R; Hsyu, PH; Loi, CM; Ono, C; Yamazaki, S | 1 |
| Asatryan, A; Jiang, P; Jungerwirth, S; Mohamed, MF; Othman, AA | 1 |
| Bessudo, A; Esseltine, DL; Gupta, N; Hanley, MJ; Ke, A; Liu, G; Nemunaitis, J; O'Neil, BH; Patel, C; Rasco, DW; Rowland Yeo, K; Sharma, S; Venkatakrishnan, K; Wang, B; Xia, C; Zhang, X | 1 |
| Daali, Y; Desmeules, JA; Marsousi, N; Rudaz, S | 1 |
| den Adel, M; Garcia-Hernandez, A; Groenendaal-van de Meent, D; Katashima, M; Kato, K; Kusawake, T; Ohtsu, Y; Takada, A | 1 |
| Gobburu, JVS; Liu, T | 1 |
| Chun, DY; Dutreix, C; Einolf, HJ; Gu, H; He, H; Ouatas, T; Rebello, S; Wang, L | 1 |
| Ahuja, N; Bhagyaraj, E; Gupta, P; Janmeja, AK; Kalra, R; Kumar, S; Nanduri, R; Saini, A; Tiwari, D | 1 |
| Dallinger, C; Jungnik, A; Luedtke, D; Marzin, K; von Wangenheim, U | 1 |
| Costales, C; Kimoto, E; Loi, CM; Varma, MV; Yamazaki, S | 1 |
| Cleary, Y; Johnson, TN; Parrott, N; Reigner, B; Smith, JR; Toovey, S | 1 |
| Arora, S; Christensen, J; Hughes, L; Lu, S; Wang, J; Wang, X; Zhang, ZY | 1 |
| Chakravarthy, M; Kraft, WK; Liu, W; Mangin, E; Martinez-Cantarin, MP; McCrea, JB; Panebianco, D; Wrishko, RE; Yee, KL | 1 |
| Cho, JY; Jang, IJ; Kim, AH; Kim, B; Lee, J; Lee, S; Yi, S; Yoon, SH; Yu, KS | 1 |
| Goosen, TC; Lin, J; Malhotra, B; Tse, S; Yamagami, H | 1 |
| Aslanis, V; He, H; Heimbach, T; Huth, F; Jin, Y; Schiller, H; Umehara, K | 1 |
| Fujino, C; Ishida, Y; Kisoh, K; Kotake, Y; Ohta, S; Sanoh, S; Sugahara, G; Tamura, Y; Tateno, C; Yanagi, A; Yoshizane, Y | 1 |
| Dickinson, GL; Hall, SD; Kulanthaivel, P; Morse, BL; Posada, MM; Turner, PK | 1 |
| Hanley, M; Iwasaki, S; Venkatakrishnan, K; Xia, C; Zhu, A | 1 |
| Fan, B; Ke, A; Le, K; Prakash, C; Yang, H | 1 |
| Chen, Y; Ding, H; Girish, S; Jin, J; Li, C; Lu, D; Ma, F; Mao, J; Miles, D; Samineni, D; Shi, R; Wright, M | 1 |
| Aman, AT; Ambara, A; Annisa, L; Darma, S; Nuryastuti, T; Wibawa, T | 1 |
9 review(s) available for ketoconazole and rifampin
| Article | Year |
|---|---|
Recently reported biological activities of pyrazole compounds.
Topics: Analgesics; Animals; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Antifungal Agents; Antineoplastic Agents; Antiviral Agents; Humans; Pyrazoles | 2017 |
Targeting breast cancer resistance protein (BCRP/ABCG2): Functional inhibitors and expression modulators.
Topics: Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily G, Member 2; Breast Neoplasms; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Proteins; Neoplastic Stem Cells | 2022 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Drug interactions: Part I.
Topics: Antidepressive Agents, Tricyclic; Caffeine; Cimetidine; Cytochrome P-450 CYP1A2; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Induction; Fluconazole; Fluoxetine; Hexobarbital; Humans; Ketoconazole; Nimodipine; Oxidoreductases; Pharmaceutical Preparations; Rifampin; Stereoisomerism; Warfarin; Zidovudine | 1992 |
Drug interactions: part II.
Topics: Amiodarone; Biological Availability; Dapsone; Didanosine; Drug Interactions; Fluconazole; Food; Humans; Intestinal Absorption; Ketoconazole; Pharmaceutical Preparations; Rifampin | 1992 |
Cyclosporine pharmacokinetic drug interactions.
Topics: Adrenal Cortex Hormones; Anticonvulsants; Calcium Channel Blockers; Cyclosporins; Erythromycin; Humans; Ketoconazole; Rifampin; Sulfonamides | 1989 |
Transporter-mediated drug interactions: clinical implications and in vitro assessment.
Topics: Animals; Area Under Curve; Cytochrome P-450 Enzyme System; Drug Interactions; Humans; Ketoconazole; Membrane Transport Proteins; Midazolam; Pharmaceutical Preparations; Rifampin | 2007 |
CYP3A4 and pregnane X receptor humanized mice.
Topics: Animals; Chromosomes, Artificial, Bacterial; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Estrogens; Forecasting; Humans; Ketoconazole; Male; Mice; Mice, Knockout; Mice, Transgenic; Midazolam; Models, Animal; Pregnane X Receptor; Receptors, Steroid; Rifampin; Sex Factors | 2007 |
Lurasidone drug-drug interaction studies: a comprehensive review.
Topics: Antipsychotic Agents; Area Under Curve; Clinical Trials, Phase I as Topic; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Diltiazem; Drug Interactions; Drug Therapy, Combination; Humans; Isoindoles; Ketoconazole; Lithium Compounds; Lurasidone Hydrochloride; Rifampin; Thiazoles | 2014 |
50 trial(s) available for ketoconazole and rifampin
| Article | Year |
|---|---|
[Pharmacokinetic interaction of ketoconazole, isoniazid and rifampicin].
Topics: Adult; Clinical Trials as Topic; Drug Interactions; Drug Therapy, Combination; Humans; Isoniazid; Ketoconazole; Male; Middle Aged; Rifampin; Tuberculosis | 1989 |
Simultaneous assessment of CYP3A4 and CYP1A2 activity in vivo with alprazolam and caffeine.
Topics: Adult; Alprazolam; Area Under Curve; Caffeine; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Enzyme Induction; Enzyme Inhibitors; Female; Humans; Ketoconazole; Male; Middle Aged; Mixed Function Oxygenases; Reference Values; Rifampin | 1999 |
The interaction of saquinavir (soft gelatin capsule) with ketoconazole, erythromycin and rifampicin: comparison of the effect in healthy volunteers and in HIV-infected patients.
Topics: Adult; Aged; Analysis of Variance; Anti-Bacterial Agents; Antifungal Agents; Area Under Curve; Biological Availability; Cross-Over Studies; Drug Administration Schedule; Drug Interactions; Erythromycin; Half-Life; HIV Infections; HIV Protease Inhibitors; Humans; Ketoconazole; Male; Middle Aged; Rifampin; Saquinavir | 2001 |
Modulation of the cytochrome P450-mediated metabolism of ifosfamide by ketoconazole and rifampin.
Topics: Adult; Aged; Antibiotics, Antitubercular; Antifungal Agents; Antineoplastic Agents, Alkylating; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Bayes Theorem; Cross-Over Studies; Cytochrome P-450 CYP2B6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Administration Schedule; Enzyme Induction; Enzyme Inhibitors; Female; Humans; Ifosfamide; Ketoconazole; Male; Middle Aged; Mixed Function Oxygenases; Oxidoreductases, N-Demethylating; Rifampin; Time Factors | 2001 |
Influence of drugs interacting with CYP3A4 on the pharmacokinetics, pharmacodynamics, and safety of the prandial glucose regulator repaglinide.
Topics: Adult; Area Under Curve; Blood Glucose; Carbamates; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Half-Life; Humans; Hypoglycemic Agents; Ketoconazole; Male; Piperidines; Rifampin; Simvastatin | 2003 |
Effect of ketoconazole and rifampicin on the pharmacokinetics of ranitidine in healthy human volunteers: a possible role of P-glycoprotein.
Topics: Adult; Analysis of Variance; Animals; Antibiotics, Antitubercular; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Cross-Over Studies; Drug Interactions; Histamine H2 Antagonists; Humans; Intestinal Absorption; Intestinal Mucosa; Ketoconazole; Male; Ranitidine; Rats; Rats, Wistar; Rifampin; Tissue Culture Techniques | 2006 |
Human intestinal P-glycoprotein activity estimated by the model substrate digoxin.
Topics: Adult; Aged; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Cardiotonic Agents; Digoxin; Drug Interactions; Duodenum; Female; Gene Expression; Homozygote; Humans; Ketoconazole; Male; Middle Aged; Polymorphism, Restriction Fragment Length; Reverse Transcriptase Polymerase Chain Reaction; Rifampin; RNA, Messenger | 2007 |
The effects of ketoconazole and rifampicin on the pharmacokinetics of mirodenafil in healthy Korean male volunteers: an open-label, one-sequence, three-period, three-treatment crossover study.
Topics: Adult; Asian People; Biological Availability; Biotransformation; Chromatography, Liquid; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Enzyme Induction; Enzyme Inhibitors; Humans; Ketoconazole; Korea; Male; Phosphodiesterase 5 Inhibitors; Phosphodiesterase Inhibitors; Pyrimidinones; Rifampin; Sulfonamides; Tandem Mass Spectrometry; Young Adult | 2009 |
Ketoconazole and rifampin significantly affect the pharmacokinetics, but not the safety or QTc interval, of casopitant, a neurokinin-1 receptor antagonist.
Topics: Adolescent; Adult; Antiemetics; Area Under Curve; Cytochrome P-450 CYP3A Inhibitors; Electrocardiography; Enzyme Induction; Humans; Ketoconazole; Middle Aged; Neurokinin-1 Receptor Antagonists; Piperazines; Piperidines; Rifampin; Young Adult | 2010 |
Unexpected effect of rifampin on the pharmacokinetics of linezolid: in silico and in vitro approaches to explain its mechanism.
Topics: Acetamides; Adult; Anti-Infective Agents; Antibiotics, Antitubercular; Area Under Curve; Cells, Cultured; Computer Simulation; Cross-Over Studies; Cytochrome P-450 CYP3A; Drug Interactions; Enzyme Induction; Half-Life; Hepatocytes; Humans; Ketoconazole; Linezolid; Male; Oxazolidinones; Rifampin; Testosterone; Tissue Distribution; Young Adult | 2011 |
Effects of rifampin and ketoconazole on the pharmacokinetics of nilotinib in healthy participants.
Topics: Adult; Area Under Curve; Cytochrome P-450 CYP3A; Drug Interactions; Enzyme Induction; Enzyme Inhibitors; Female; Humans; Hydrocortisone; Ketoconazole; Male; Pyrimidines; Rifampin; Young Adult | 2011 |
The influence of modulation of P-glycoprotein and /or cytochrome P450 3A on the pharmacokinetics and pharmacodynamics of orally administered morphine in dogs.
Topics: Absorption; Acridines; Administration, Oral; Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dogs; Enzyme Inhibitors; Female; Ketoconazole; Male; Morphine; Rifampin; Tetrahydroisoquinolines | 2011 |
Concurrent assessment of hepatic and intestinal cytochrome P450 3A activities using deuterated alfentanil.
Topics: Administration, Oral; Adult; Alfentanil; Anesthetics, Intravenous; Area Under Curve; Beverages; Citrus paradisi; Cross-Over Studies; Cytochrome P-450 CYP3A; Deuterium; Drug Administration Schedule; Enzyme Induction; Enzyme Inhibitors; Female; Humans; Intestinal Mucosa; Ketoconazole; Liver; Male; Miosis; Rifampin; Young Adult | 2011 |
The effect of CYP3A4 inhibition or induction on the pharmacokinetics and pharmacodynamics of orally administered ruxolitinib (INCB018424 phosphate) in healthy volunteers.
Topics: Adult; Antineoplastic Agents; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Enzyme Induction; Enzyme Inhibitors; Erythromycin; Female; Half-Life; Humans; Janus Kinase 1; Janus Kinase 2; Ketoconazole; Male; Metabolic Detoxication, Phase I; Middle Aged; Nitriles; Phosphorylation; Protein Kinase Inhibitors; Pyrazoles; Pyrimidines; Rifampin; STAT3 Transcription Factor; Young Adult | 2012 |
Effects of CYP3A4 inhibition and induction on the pharmacokinetics and pharmacodynamics of tolvaptan, a non-peptide AVP antagonist in healthy subjects.
Topics: 14-alpha Demethylase Inhibitors; Adolescent; Adult; Antidiuretic Hormone Receptor Antagonists; Area Under Curve; Benzazepines; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Double-Blind Method; Drug Interactions; Enzyme Inhibitors; Female; Humans; Ketoconazole; Male; Middle Aged; Rifampin; Tolvaptan; Urination; Young Adult | 2012 |
The effect of multiple doses of rifampin and ketoconazole on the single-dose pharmacokinetics of ridaforolimus.
Topics: Adult; Antineoplastic Agents; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cytochrome P-450 CYP3A; Drug Interactions; Half-Life; Humans; Ketoconazole; Male; Middle Aged; Rifampin; Sirolimus; Young Adult | 2012 |
Evaluation of the effects of rifampicin, ketoconazole and erythromycin on the steady-state pharmacokinetics of the components of a novel oral contraceptive containing estradiol valerate and dienogest in healthy postmenopausal women.
Topics: Aged; Anti-Infective Agents; Biotransformation; Contraceptives, Oral, Combined; Contraceptives, Oral, Hormonal; Cross-Over Studies; Cytochrome P-450 CYP3A; Drug Combinations; Drug Interactions; Enzyme Induction; Erythromycin; Estradiol; Estrogen Replacement Therapy; Estrone; Female; Humans; Ketoconazole; Middle Aged; Nandrolone; Postmenopause; Rifampin | 2012 |
Effects of ketoconazole and rifampicin on the pharmacokinetics of gemigliptin, a dipeptidyl peptidase-IV inhibitor: a crossover drug-drug interaction study in healthy male Korean volunteers.
Topics: Administration, Oral; Adult; Area Under Curve; Asian People; Chromatography, Liquid; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dipeptidyl-Peptidase IV Inhibitors; Drug Administration Schedule; Drug Interactions; Enzyme Inhibitors; Humans; Ketoconazole; Male; Organic Chemicals; Piperidones; Pyrimidines; Republic of Korea; Rifampin; Tandem Mass Spectrometry; Time Factors; Young Adult | 2012 |
Phase I evaluation of the effects of ketoconazole and rifampicin on cediranib pharmacokinetics in patients with solid tumours.
Topics: Adult; Aged; Area Under Curve; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Humans; Ketoconazole; Middle Aged; Neoplasms; Quinazolines; Receptors, Vascular Endothelial Growth Factor; Rifampin; Young Adult | 2013 |
Increased systemic exposure of fimasartan, an angiotensin II receptor antagonist, by ketoconazole and rifampicin.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Animals; Area Under Curve; Biphenyl Compounds; Cells, Cultured; Cross-Over Studies; Drug Interactions; Humans; Ketoconazole; Liver-Specific Organic Anion Transporter 1; Male; Oocytes; Organic Anion Transport Protein 1; Organic Anion Transporters; Pyrimidines; Rifampin; Tetrazoles; Xenopus laevis; Young Adult | 2013 |
The effect of multiple doses of ketoconazole or rifampin on the single- and multiple-dose pharmacokinetics of vorapaxar.
Topics: Adult; Aged; Cytochrome P-450 CYP3A; Female; Humans; Ketoconazole; Lactones; Male; Middle Aged; Platelet Aggregation Inhibitors; Pyridines; Rifampin; Young Adult | 2013 |
Role of cytochrome p450 isoenzymes 3A and 2D6 in the in vivo metabolism of mirabegron, a β3-adrenoceptor agonist.
Topics: Acetanilides; Adolescent; Adrenergic beta-3 Receptor Agonists; Adult; Area Under Curve; Cross-Over Studies; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Drug Interactions; Female; Half-Life; Humans; Ketoconazole; Male; Middle Aged; Rifampin; Thiazoles; Young Adult | 2013 |
CYP3A-mediated drug-drug interaction potential and excretion of brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive hematologic malignancies.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Brentuximab Vedotin; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Feces; Female; Hematologic Neoplasms; Humans; Immunoconjugates; Ketoconazole; Ki-1 Antigen; Male; Midazolam; Middle Aged; Oligopeptides; Rifampin; Young Adult | 2013 |
Evaluation of endogenous metabolic markers of hepatic CYP3A activity using metabolic profiling and midazolam clearance.
Topics: Adult; Biomarkers; Cortisone; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Enzyme Induction; Gas Chromatography-Mass Spectrometry; Humans; Hydrocortisone; Hydroxycholesterols; Ketoconazole; Liver; Male; Metabolomics; Midazolam; Pharmacogenetics; Rifampin; Young Adult | 2013 |
Effects of cytochrome P450 inhibitors and inducers on the metabolism and pharmacokinetics of ospemifene.
Topics: Aged; Aged, 80 and over; Cross-Over Studies; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Estrogen Receptor Modulators; Female; Humans; Ketoconazole; Microsomes, Liver; Middle Aged; Postmenopause; Rifampin; Tamoxifen | 2013 |
Pharmacokinetic drug interactions involving vortioxetine (Lu AA21004), a multimodal antidepressant.
Topics: Adolescent; Adult; Antidepressive Agents; Antifungal Agents; Bupropion; Cohort Studies; Contraceptives, Oral, Hormonal; Cross-Over Studies; Drug Interactions; Enzyme Induction; Enzyme Inhibitors; Female; Fluconazole; Humans; Ketoconazole; Male; Middle Aged; Omeprazole; Piperazines; Rifampin; Single-Blind Method; Sulfides; Vortioxetine; Young Adult | 2013 |
Investigation into CYP3A4-mediated drug-drug interactions on midostaurin in healthy volunteers.
Topics: Adult; Antineoplastic Agents; Chromatography, Liquid; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Administration Schedule; Drug Interactions; Enzyme Induction; Enzyme Inhibitors; Female; Humans; Ketoconazole; Male; Midazolam; Middle Aged; Rifampin; Staurosporine; Tandem Mass Spectrometry; Young Adult | 2013 |
Simultaneous determination of probe drugs, metabolites, inhibitors and inducer in human plasma by liquid chromatography/tandem mass spectrometry and its application to pharmacokinetic study.
Topics: Calibration; Chromatography, Liquid; Cross-Over Studies; Cytochrome P-450 CYP3A; Freezing; Glucuronosyltransferase; Healthy Volunteers; Humans; Ketoconazole; Midazolam; Particle Size; Pyrrolidinones; Quality Control; Raltegravir Potassium; Reproducibility of Results; Rifampin; Ritonavir; Solid Phase Extraction; Tandem Mass Spectrometry; Xenobiotics | 2014 |
Population pharmacokinetics of the 5-hydroxymethyl metabolite of tolterodine after administration of fesoterodine sustained release tablet in Western and East Asian populations.
Topics: Adult; Aged; Aged, 80 and over; Asian People; Benzhydryl Compounds; Creatinine; Cresols; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Delayed-Action Preparations; Female; Genotype; Humans; Ketoconazole; Liver Diseases; Male; Middle Aged; Models, Biological; Muscarinic Antagonists; Rifampin; Tablets; Urinary Bladder, Overactive; Urological Agents; White People; Young Adult | 2014 |
Validation of 4β-hydroxycholesterol and evaluation of other endogenous biomarkers for the assessment of CYP3A activity in healthy subjects.
Topics: Adolescent; Adult; Biomarkers; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Healthy Volunteers; Humans; Hydroxycholesterols; Injections, Intravenous; Ketoconazole; Limit of Detection; Midazolam; Middle Aged; Rifampin; Saliva; Substrate Specificity; Time Factors; Tissue Distribution; Young Adult | 2014 |
The impact of co-administration of ketoconazole and rifampicin on the pharmacokinetics of apremilast in healthy volunteers.
Topics: Administration, Oral; Adolescent; Adult; Area Under Curve; Carrier Proteins; Cytochrome P-450 Enzyme System; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Female; Healthy Volunteers; Humans; Ketoconazole; Male; Middle Aged; Phosphodiesterase 4 Inhibitors; Rifampin; Substrate Specificity; Thalidomide; Young Adult | 2014 |
Impact of cytochrome P450 3A4 inducer and inhibitor on the pharmacokinetics of trabectedin in patients with advanced malignancies: open-label, multicenter studies.
Topics: Adult; Antineoplastic Agents; Cytochrome P-450 CYP3A; Dioxoles; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Antagonism; Drug Monitoring; Drug Screening Assays, Antitumor; Drug-Related Side Effects and Adverse Reactions; Enzyme Activators; Enzyme Inhibitors; Female; Humans; Ketoconazole; Male; Metabolic Clearance Rate; Neoplasm Invasiveness; Neoplasm Staging; Neoplasms; Rifampin; Tetrahydroisoquinolines; Trabectedin; Treatment Outcome | 2014 |
Phase I study of cabazitaxel plus cisplatin in patients with advanced solid tumors: study to evaluate the impact of cytochrome P450 3A inhibitors (aprepitant, ketoconazole) or inducers (rifampin) on the pharmacokinetics of cabazitaxel.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Aprepitant; Area Under Curve; Cisplatin; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 Enzyme Inducers; Drug Interactions; Female; Humans; Ketoconazole; Male; Middle Aged; Morpholines; Neoplasms; Rifampin; Taxoids | 2014 |
Pharmacokinetic (PK) drug interaction studies of cabozantinib: Effect of CYP3A inducer rifampin and inhibitor ketoconazole on cabozantinib plasma PK and effect of cabozantinib on CYP2C8 probe substrate rosiglitazone plasma PK.
Topics: Anilides; Antineoplastic Agents; Area Under Curve; Cytochrome P-450 CYP2C8; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Half-Life; Humans; Hypoglycemic Agents; Ketoconazole; Microsomes, Liver; Pyridines; Receptor Protein-Tyrosine Kinases; Rifampin; Rosiglitazone; Thiazolidinediones | 2015 |
Evaluation of CYP3A-mediated drug-drug interactions with romidepsin in patients with advanced cancer.
Topics: Adult; Aged; Aged, 80 and over; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Depsipeptides; Drug Interactions; Female; Humans; Ketoconazole; Male; Middle Aged; Neoplasms; Rifampin | 2015 |
Prediction of Drug-Drug Interactions with Crizotinib as the CYP3A Substrate Using a Physiologically Based Pharmacokinetic Model.
Topics: Adult; Crizotinib; Cross-Over Studies; Cytochrome P-450 CYP3A; Drug Interactions; Female; Forecasting; Humans; Ketoconazole; Male; Middle Aged; Models, Biological; Pyrazoles; Pyridines; Rifampin; Substrate Specificity | 2015 |
Exploratory effects of a strong CYP3A inhibitor (ketoconazole), a strong CYP3A inducer (rifampicin), and concomitant ethanol on piragliatin pharmacokinetics and pharmacodynamics in type 2 diabetic patients.
Topics: Adult; Aged; Benzeneacetamides; Blood Glucose; Cross-Over Studies; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Diabetes Mellitus, Type 2; Double-Blind Method; Ethanol; Female; Humans; Hypoglycemic Agents; Ketoconazole; Male; Middle Aged; Rifampin | 2016 |
The effects of ketoconazole and rifampin on the single-dose pharmacokinetics of crizotinib in healthy subjects.
Topics: Adult; Area Under Curve; Crizotinib; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Female; Humans; Ketoconazole; Male; Middle Aged; Pyrazoles; Pyridines; Rifampin | 2015 |
Effects of CYP3A4 Inhibitors Ketoconazole and Verapamil and the CYP3A4 Inducer Rifampicin on the Pharmacokinetic Parameters of Fostamatinib: Results from In Vitro and Phase I Clinical Studies.
Topics: Adult; Aminopyridines; Cross-Over Studies; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Double-Blind Method; Drug Interactions; Humans; Ketoconazole; Male; Microsomes, Liver; Morpholines; Oxazines; Pyridines; Pyrimidines; Rifampin; Verapamil; Young Adult | 2016 |
The effects of CYP3A4 induction and inhibition on the pharmacokinetics of alisporivir in humans.
Topics: Area Under Curve; Azithromycin; Belgium; Biotransformation; Cross-Over Studies; Cyclosporine; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Female; Florida; Half-Life; Humans; Immunosuppressive Agents; Ketoconazole; Male; Metabolic Clearance Rate; Models, Biological; New York; Rifampin; Substrate Specificity | 2015 |
Effects of ketoconazole or rifampin on the pharmacokinetics of tivozanib hydrochloride, a vascular endothelial growth factor receptor tyrosine kinase inhibitor.
Topics: Administration, Oral; Adolescent; Adult; Angiogenesis Inhibitors; Area Under Curve; Biotransformation; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Female; Half-Life; Humans; Ketoconazole; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Phenylurea Compounds; Protein Kinase Inhibitors; Quinolines; Receptors, Vascular Endothelial Growth Factor; Rifampin; United States; Young Adult | 2015 |
Urinary 6β-Hydroxycortisol/Cortisol Ratio Most Highly Correlates With Midazolam Clearance Under Hepatic CYP3A Inhibition and Induction in Females: A Pharmacometabolomics Approach.
Topics: Administration, Intravenous; Administration, Oral; Adult; Biomarkers; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Enzyme Induction; Female; Humans; Hydrocortisone; Ketoconazole; Liver; Metabolic Clearance Rate; Metabolomics; Midazolam; Middle Aged; Rifampin; Young Adult | 2016 |
Ibrutinib Dosing Strategies Based on Interaction Potential of CYP3A4 Perpetrators Using Physiologically Based Pharmacokinetic Modeling.
Topics: Adenine; Alkynes; Azithromycin; Benzoxazines; Carbamazepine; Cyclopropanes; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Drug Dosage Calculations; Drug Interactions; Fluvoxamine; Humans; Ketoconazole; Male; Models, Biological; Piperidines; Pyrazoles; Pyrimidines; Rifampin | 2016 |
A Physiologically-Based Pharmacokinetic Modeling Approach To Predict Drug-Drug Interactions of Sonidegib (LDE225) with Perpetrators of CYP3A in Cancer Patients.
Topics: Adult; Biphenyl Compounds; Computer Simulation; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Female; Healthy Volunteers; Humans; Ketoconazole; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Neoplasms; Pyridines; Rifampin; Smoothened Receptor; Time Factors; Young Adult | 2017 |
Assessment of effect of CYP3A inhibition, CYP induction, OATP1B inhibition, and high-fat meal on pharmacokinetics of the JAK1 inhibitor upadacitinib.
Topics: Adult; Area Under Curve; Autoimmune Diseases; Cross-Over Studies; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Diet, High-Fat; Dietary Fats; Drug Interactions; Fasting; Female; Food-Drug Interactions; Healthy Volunteers; Heterocyclic Compounds, 3-Ring; Humans; Janus Kinase 1; Ketoconazole; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Protein Kinase Inhibitors; Rifampin; Young Adult | 2017 |
Effects of Strong CYP3A Inhibition and Induction on the Pharmacokinetics of Ixazomib, an Oral Proteasome Inhibitor: Results of Drug-Drug Interaction Studies in Patients With Advanced Solid Tumors or Lymphoma and a Physiologically Based Pharmacokinetic Ana
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Boron Compounds; Clarithromycin; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Female; Glycine; Humans; Ketoconazole; Male; Middle Aged; Models, Biological; Neoplasms; Proteasome Inhibitors; Rifampin | 2018 |
Effects of Ketoconazole and Rifampicin on the Pharmacokinetics of Nintedanib in Healthy Subjects.
Topics: Administration, Oral; Adolescent; Adult; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Cross-Over Studies; Drug Administration Schedule; Drug Interactions; Germany; Healthy Volunteers; Humans; Indoles; Intestinal Absorption; Ketoconazole; Male; Middle Aged; Models, Biological; Rifampin; Risk Assessment; Young Adult | 2018 |
Pharmacokinetic Interactions of Rolapitant With Cytochrome P450 3A Substrates in Healthy Subjects.
Topics: Administration, Oral; Adult; Area Under Curve; Cytochrome P-450 CYP3A; Drug Interactions; Female; Humans; Ketoconazole; Male; Midazolam; Middle Aged; Neurokinin-1 Receptor Antagonists; Rifampin; Spiro Compounds | 2019 |
Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects.
Topics: Administration, Oral; Adult; Azepines; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Diltiazem; Drug Interactions; Healthy Volunteers; Humans; Ketoconazole; Male; Middle Aged; Orexin Receptor Antagonists; Rifampin; Triazoles; Young Adult | 2019 |
Quantitative prediction of hepatic CYP3A activity using endogenous markers in healthy subjects after administration of CYP3A inhibitors or inducers.
Topics: Adult; Biomarkers; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Healthy Volunteers; Humans; Itraconazole; Ketoconazole; Male; Midazolam; Rifampin; Young Adult | 2019 |
105 other study(ies) available for ketoconazole and rifampin
| Article | Year |
|---|---|
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
The antitubercular activity of various nitro(triazole/imidazole)-based compounds.
Topics: Animals; Antitubercular Agents; Cell Line; Chlorocebus aethiops; Dose-Response Relationship, Drug; Humans; Imidazoles; Macrophages; Mice; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Nitro Compounds; Structure-Activity Relationship; Triazoles | 2017 |
Discovery of a Conformationally Constrained Oxazolidinone with Improved Safety and Efficacy Profiles for the Treatment of Multidrug-Resistant Tuberculosis.
Topics: Animals; Chlorocebus aethiops; Drug Design; Female; Hep G2 Cells; Humans; Mice; Microbial Sensitivity Tests; Molecular Conformation; Mycobacterium tuberculosis; Oxazolidinones; Safety; Tuberculosis, Multidrug-Resistant; Vero Cells | 2020 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
OPC-67683, a nitro-dihydro-imidazooxazole derivative with promising action against tuberculosis in vitro and in mice.
Topics: Animals; Antitubercular Agents; Blood; Cell Line; Humans; In Vitro Techniques; Intracellular Membranes; Macrophages; Mammals; Mice; Microbial Sensitivity Tests; Microsomes, Liver; Mycobacterium; Mycobacterium bovis; Mycolic Acids; Nitroimidazoles; Oxazoles; Treatment Outcome; Tuberculosis | 2006 |
Three-dimensional quantitative structure-activity relationship analysis of human CYP51 inhibitors.
Topics: Amides; Cytochrome P-450 Enzyme Inhibitors; Enzyme Inhibitors; Humans; Indoles; Models, Molecular; Oxidoreductases; Quantitative Structure-Activity Relationship; Sterol 14-Demethylase | 2007 |
Low-oxygen-recovery assay for high-throughput screening of compounds against nonreplicating Mycobacterium tuberculosis.
Topics: Anti-Bacterial Agents; Antitubercular Agents; DNA, Bacterial; Drug Evaluation, Preclinical; Mycobacterium tuberculosis; Oxygen | 2007 |
Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).
Topics: Administration, Oral; Animals; Antineoplastic Agents; Antipsychotic Agents; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biological Transport; Cell Line; Computer Simulation; Cytochrome P-450 Enzyme System; Drug-Related Side Effects and Adverse Reactions; Estradiol; Humans; Insecta; Liver; Models, Molecular; Multidrug Resistance-Associated Protein 2; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Pharmaceutical Preparations; Pharmacology; Structure-Activity Relationship | 2008 |
Synthesis of novel ketoconazole derivatives as inhibitors of the human Pregnane X Receptor (PXR; NR1I2; also termed SXR, PAR).
Topics: Binding Sites; Catalysis; Cell Line, Tumor; Chemistry, Pharmaceutical; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Design; Drug Interactions; Humans; Inhibitory Concentration 50; Ketoconazole; Microsomes, Liver; Models, Chemical; Pregnane X Receptor; Receptors, Steroid | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Antimicrobial ambiguine isonitriles from the cyanobacterium Fischerella ambigua.
Topics: Anti-Bacterial Agents; Bacillus anthracis; Cyanobacteria; Indole Alkaloids; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Nuclear Magnetic Resonance, Biomolecular | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Synthesis and evaluation of anti-Toxoplasma gondii and antimicrobial activities of thiosemicarbazides, 4-thiazolidinones and 1,3,4-thiadiazoles.
Topics: Animals; Anti-Infective Agents; Antiprotozoal Agents; Bacteria; Chlorocebus aethiops; Drug Resistance; Fungi; Intracellular Space; Microbial Sensitivity Tests; Semicarbazides; Thiazolidines; Toxoplasma; Vero Cells | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Analysis of physico-chemical properties of substrates of ABC and MFS multidrug transporters of pathogenic Candida albicans.
Topics: Candida albicans; Membrane Transport Proteins; Saccharomyces cerevisiae; Structure-Activity Relationship; Substrate Specificity | 2010 |
Predicting phospholipidosis using machine learning.
Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Cholestasis; Drug-Related Side Effects and Adverse Reactions; Humans; Insecta; Rats; Risk Factors | 2012 |
Species-dependent and receptor-selective action of bilobalide on the function of constitutive androstane receptor and pregnane X receptor.
Topics: Animals; Cell Line, Tumor; Cells, Cultured; Constitutive Androstane Receptor; Cyclopentanes; Furans; Ginkgolides; Hep G2 Cells; Hepatocytes; Humans; Pregnane X Receptor; Rats; Receptors, Cytoplasmic and Nuclear; Receptors, Steroid; Species Specificity | 2012 |
Synthesis of benzimidazolyl-1,3,4-oxadiazol-2ylthio-N-phenyl (benzothiazolyl) acetamides as antibacterial, antifungal and antituberculosis agents.
Topics: Antifungal Agents; Antitubercular Agents; Bacteria; Benzothiazoles; Chemistry Techniques, Synthetic; Fungi; Microbial Sensitivity Tests; Mycobacterium tuberculosis | 2012 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Hytramycins V and I, anti-Mycobacterium tuberculosis hexapeptides from a Streptomyces hygroscopicus strain.
Topics: Animals; Antitubercular Agents; Chlorocebus aethiops; Chromatography, High Pressure Liquid; Inhibitory Concentration 50; Microbial Sensitivity Tests; Molecular Structure; Mycobacterium tuberculosis; Nuclear Magnetic Resonance, Biomolecular; Peptides, Cyclic; Streptomyces; Vero Cells | 2013 |
A high-throughput cell-based method to predict the unbound drug fraction in the brain.
Topics: Animals; Brain; Dialysis; HEK293 Cells; High-Throughput Screening Assays; Humans; Pharmaceutical Preparations; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 2014 |
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Chemical and Drug Induced Liver Injury; Humans; Male; Mitochondria, Liver; Rats; Rats, Sprague-Dawley; Severity of Illness Index | 2014 |
2-(3-Methoxyphenyl)quinazoline Derivatives: A New Class of Direct Constitutive Androstane Receptor (CAR) Agonists.
Topics: Constitutive Androstane Receptor; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Enzyme Inhibitors; Hep G2 Cells; Hepatocytes; Humans; Models, Molecular; Molecular Structure; Quinazolines; Receptors, Cytoplasmic and Nuclear; Structure-Activity Relationship | 2016 |
Synthesis, SAR and molecular docking studies of benzo[d]thiazole-hydrazones as potential antibacterial and antifungal agents.
Topics: Anti-Bacterial Agents; Antifungal Agents; Aspergillus niger; Bacterial Proteins; Benzothiazoles; Binding Sites; Fusarium; Gram-Negative Bacteria; Gram-Positive Bacteria; Hydrazones; Microbial Sensitivity Tests; Molecular Docking Simulation; Protein Structure, Tertiary; Structure-Activity Relationship | 2017 |
Interaction of azoles with rifampin, phenytoin, and carbamazepine: in vitro and clinical observations.
Topics: Adult; Aged; Antifungal Agents; Azoles; Carbamazepine; Coccidioides; Cryptococcus neoformans; Drug Interactions; Drug Therapy, Combination; Female; Fluconazole; Humans; Itraconazole; Ketoconazole; Malassezia; Male; Middle Aged; Mycoses; Phenytoin; Rifampin | 1992 |
The treatment of diffuse cutaneous leishmaniasis: a report of two cases.
Topics: Adolescent; Adult; Antimony Sodium Gluconate; Biopsy; Female; Humans; Isoniazid; Ketoconazole; Leishmaniasis; Levamisole; Male; Rifampin; Ultraviolet Therapy | 1991 |
Sporotrichoid infection. Two cases.
Topics: Aged; Biopsy; Diagnosis, Differential; Female; Humans; Itraconazole; Ketoconazole; Male; Middle Aged; Mycobacterium Infections, Nontuberculous; Nontuberculous Mycobacteria; Rifampin; Skin Diseases, Infectious; Sporothrix; Sporotrichosis | 1990 |
Sinus and nasal manifestations of the acquired immunodeficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Amphotericin B; Anti-Bacterial Agents; HIV Seropositivity; Humans; Ketoconazole; Nasopharyngeal Diseases; Opportunistic Infections; Paranasal Sinus Diseases; Rifampin; Therapeutic Irrigation | 1990 |
Update on rifampin drug interactions.
Topics: Adrenergic beta-Antagonists; Cyclosporins; Digoxin; Drug Interactions; Humans; Ketoconazole; Phenytoin; Rifampin; Theophylline; Verapamil | 1987 |
Effects of bifonazole, fluconazole, itraconazole, and terbinafine on the chemiluminescence response of immune cells.
Topics: Animals; Antifungal Agents; Cell Survival; Centrifugation; Fluconazole; Imidazoles; In Vitro Techniques; Itraconazole; Ketoconazole; Luminescent Measurements; Luminol; Mice; Mice, Inbred BALB C; Naphthalenes; Phagocytes; Rabbits; Rifampin; Spleen; Terbinafine; Triazoles | 1987 |
Adrenal mass in an immunocompromised man.
Topics: Abscess; Adrenal Gland Diseases; Amphotericin B; Aspergillosis; Aspergillus fumigatus; Diagnosis, Differential; Drainage; Drug Therapy, Combination; Humans; Ketoconazole; Male; Middle Aged; Opportunistic Infections; Rifampin; Sarcoidosis | 1988 |
Failure of ketoconazole treatment of Blastomyces dermatitidis [corrected] due to interaction of isoniazid and rifampin.
Topics: Blastomycosis; Drug Interactions; Female; Humans; Isoniazid; Ketoconazole; Middle Aged; Rifampin | 1988 |
Pharmacokinetic study of the interaction between rifampicin and ketoconazole.
Topics: Drug Interactions; Humans; Ketoconazole; Male; Opportunistic Infections; Rifampin | 1988 |
Evaluation of single-drug and combination antifungal therapy in an experimental model of candidiasis in rabbits with prolonged neutropenia.
Topics: Agranulocytosis; Amphotericin B; Animals; Antifungal Agents; Candidiasis; Cytarabine; Drug Evaluation, Preclinical; Drug Therapy, Combination; Female; Flucytosine; Ketoconazole; Neutropenia; Rabbits; Rifampin | 1988 |
Serum fungistatic and fungicidal activity in volunteers receiving antifungal agents.
Topics: Aspergillus fumigatus; Candida; Candida albicans; Chromatography, High Pressure Liquid; Cryptococcus neoformans; Drug Evaluation; Drug Synergism; Drug Therapy, Combination; Humans; Ketoconazole; Mucorales; Mycoses; Rifampin; Triazoles | 1986 |
Simultaneous treatment with rifampin and ketoconazole.
Topics: Dermatitis; Drug Therapy, Combination; Humans; Ketoconazole; Rifampin; Staphylococcal Infections; Streptococcal Infections | 1986 |
Pulmonary Mycobacterium tuberculosis in acquired immune deficiency syndrome.
Topics: Acquired Immunodeficiency Syndrome; Adult; Drug Interactions; Humans; Injections, Intravenous; Ketoconazole; Male; Rifampin; Tuberculosis, Pulmonary | 1985 |
Interaction of ketoconazole with rifampin and isoniazid.
Topics: Child, Preschool; Drug Interactions; Humans; Isoniazid; Ketoconazole; Male; Rifampin | 1985 |
Wangiella dermatitidis endocarditis in an intravenous drug user.
Topics: Adult; Amphotericin B; Aortic Valve; Drug Therapy, Combination; Endocarditis; Heart Valve Diseases; Heroin Dependence; Humans; Ketoconazole; Male; Mitosporic Fungi; Mycoses; Recurrence; Reoperation; Rifampin | 1985 |
The effect of ketoconazole and a combination of rifampicin/amphotericin B on cutaneous leishmaniasis in laboratory mice.
Topics: Amphotericin B; Animals; Drug Therapy, Combination; Ketoconazole; Leishmaniasis; Male; Mice; Mice, Inbred BALB C; Rifampin | 1984 |
Interaction of ketoconazole with rifampin and isoniazid.
Topics: Drug Interactions; Drug Therapy, Combination; Humans; Infant; Isoniazid; Ketoconazole; Kinetics; Rifampin; Tinea Capitis; Tuberculosis, Lymph Node | 1984 |
In vitro activities of miconazole, miconazole nitrate, and ketoconazole alone and combined with rifampin against Candida spp. and Torulopsis glabrata recovered from cancer patients.
Topics: Antifungal Agents; Candida; Drug Synergism; Humans; Imidazoles; Ketoconazole; Miconazole; Microbial Sensitivity Tests; Neoplasms; Piperazines; Rifampin | 1980 |
Disposition of ketoconazole, an oral antifungal, in humans.
Topics: Administration, Oral; Adult; Antacids; Antifungal Agents; Child; Drug Interactions; Humans; Imidazoles; Ketoconazole; Kidney Diseases; Kinetics; Liver Diseases; Male; Piperazines; Rifampin; Saliva; Tissue Distribution | 1982 |
Susceptibility of dermatiaceous fungi to amphotericin B, miconazole, ketoconazole, flucytosine and rifampin alone and in combination.
Topics: Amphotericin B; Antifungal Agents; Cladosporium; Drug Synergism; Flucytosine; Imidazoles; Ketoconazole; Miconazole; Microbial Sensitivity Tests; Mitosporic Fungi; Piperazines; Rifampin | 1982 |
Activity of oral drugs against Leishmania tropica in human macrophages in vitro.
Topics: Antiprotozoal Agents; Cells, Cultured; Drug Interactions; Humans; Isoniazid; Ketoconazole; Leishmania; Macrophages; Metronidazole; Nitrofurans; Phenothiazines; Quinacrine; Rifampin; Sulfamethoxazole; Trimethoprim | 1983 |
In vitro activities of amphotericin B in combination with four antifungal agents and rifampin against Aspergillus spp.
Topics: Amphotericin B; Antifungal Agents; Aspergillus; Flucytosine; Ketoconazole; Microbial Sensitivity Tests; Rifampin; Triazoles | 1984 |
Differentiation of absorption and first-pass gut and hepatic metabolism in humans: studies with cyclosporine.
Topics: Administration, Oral; Biological Availability; Cyclosporine; Drug Interactions; Erythromycin; Humans; Immunosuppressive Agents; Injections, Intravenous; Intestinal Absorption; Intestinal Mucosa; Ketoconazole; Kidney Transplantation; Liver; Protein Synthesis Inhibitors; Rifampin | 1995 |
Clinical management of tacrolimus drug interactions in renal transplant patients.
Topics: Adult; Aged; Antifungal Agents; Candidiasis; Drug Interactions; Erythromycin; Female; Humans; Immunosuppressive Agents; Ketoconazole; Kidney Transplantation; Male; Phenytoin; Postoperative Complications; Rifampin; Tacrolimus | 1999 |
Successful treatment of Acanthamoeba meningitis with combination oral antimicrobials.
Topics: Acanthamoeba; Administration, Oral; Amebiasis; Animals; Anti-Infective Agents; Antifungal Agents; Child; Child, Preschool; Chronic Disease; Drug Therapy, Combination; Enzyme Inhibitors; Female; Humans; Ketoconazole; Magnetic Resonance Imaging; Male; Meningitis; Rifampin; Trimethoprim, Sulfamethoxazole Drug Combination | 2001 |
Metabolism of amiodarone (Part III): identification of rabbit cytochrome P450 isoforms involved in the hydroxylation of mono-N-desethylamiodarone.
Topics: Amiodarone; Animals; Anti-Anxiety Agents; Anti-Arrhythmia Agents; Aryl Hydrocarbon Hydroxylases; Benzoflavones; Chromatography, High Pressure Liquid; Cimetidine; Cyclosporine; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Enzyme Inhibitors; Ketoconazole; Kinetics; Microsomes, Liver; Midazolam; Models, Chemical; Oxidoreductases, N-Demethylating; Protein Isoforms; Quinidine; Rabbits; Rifampin; Time Factors | 2001 |
Putative role of the orphan nuclear receptor SXR (steroid and xenobiotic receptor) in the mechanism of CYP3A4 inhibition by xenobiotics.
Topics: Adrenal Cortex Hormones; Animals; Antibiotics, Antitubercular; Antifungal Agents; Cell Line; Cell Nucleus; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Genes, Reporter; Humans; Ketoconazole; Ligands; Luciferases; Mixed Function Oxygenases; Models, Genetic; Plasmids; Pregnane X Receptor; Promoter Regions, Genetic; Protein Binding; Receptors, Steroid; Rifampin; Transcription, Genetic; Transcriptional Activation; Transfection; Two-Hybrid System Techniques; Xenobiotics | 2002 |
Expression of the human CYP3A4 gene in the small intestine of transgenic mice: in vitro metabolism and pharmacokinetics of midazolam.
Topics: Administration, Oral; Animals; Area Under Curve; Biological Availability; Blotting, Southern; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Dexamethasone; Drug Interactions; Enzyme Inhibitors; Half-Life; Humans; In Vitro Techniques; Intestine, Small; Ketoconazole; Male; Mice; Mice, Transgenic; Microsomes; Midazolam; Polymerase Chain Reaction; Rifampin; Time Factors | 2003 |
Effect of various cytochrome P450 3A and P-glycoprotein modulators on the biliary clearance of bromosulphaphthalein in male wistar rats.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bile; Butyrates; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Doxorubicin; Enzyme Induction; Enzyme Inhibitors; Erythromycin; Etoposide; Indinavir; Infusions, Intravenous; Isoenzymes; Ketoconazole; Male; Nitrendipine; Quinidine; Rats; Rats, Wistar; Rifampin; Sulfobromophthalein | 2004 |
Development of a fluorescence-based assay for screening of modulators of human organic anion transporter 1B3 (OATP1B3).
Topics: Aniline Compounds; Cell Line; Drug Evaluation, Preclinical; Fluorescent Dyes; Humans; Inhibitory Concentration 50; Ketoconazole; Multidrug Resistance-Associated Protein 2; Organic Anion Transporters, Sodium-Independent; Ouabain; Rifampin; Solute Carrier Organic Anion Transporter Family Member 1B3; Transfection; Xanthenes | 2006 |
A simultaneous assessment of CYP3A4 metabolism and induction in the DPX-2 cell line.
Topics: Carcinoma, Hepatocellular; Cell Line, Tumor; Chromans; Clotrimazole; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dexamethasone; Dimethyl Sulfoxide; Enhancer Elements, Genetic; Enzyme Induction; Genes, Reporter; Genes, Synthetic; Humans; Ketoconazole; Liver Neoplasms; Lovastatin; Luciferases; Mifepristone; Neoplasm Proteins; Nifedipine; Omeprazole; Paclitaxel; Phenytoin; Pregnane X Receptor; Receptors, Cytoplasmic and Nuclear; Receptors, Steroid; Recombinant Fusion Proteins; Rifampin; Thiazolidinediones; Transcription, Genetic; Troglitazone; Troleandomycin | 2005 |
Possible inhibitory mechanism of Curcuma drugs on CYP3A4 in 1alpha,25 dihydroxyvitamin D3 treated Caco-2 cells.
Topics: Caco-2 Cells; Calcitriol; Cell Survival; Curcuma; Curcumin; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Dose-Response Relationship, Drug; Enzyme Induction; Enzyme Inhibitors; Herb-Drug Interactions; Humans; Hydroxylation; Inhibitory Concentration 50; Intestinal Mucosa; Ketoconazole; Nifedipine; Oxidation-Reduction; Plant Extracts; Rhizome; Rifampin; RNA, Messenger; Testosterone | 2007 |
Activity of ketoconazole against Mycobacterium tuberculosis in vitro and in the mouse model.
Topics: Administration, Oral; Animals; Antibiotics, Antitubercular; Antitubercular Agents; Drug Evaluation, Preclinical; Drug Synergism; Drug Therapy, Combination; Female; Isoniazid; Ketoconazole; Mice; Mice, Inbred BALB C; Microbial Sensitivity Tests; Mycobacterium tuberculosis; Pyrazinamide; Rifampin; Time Factors; Treatment Outcome; Tuberculosis, Pulmonary | 2007 |
A double transgenic mouse model expressing human pregnane X receptor and cytochrome P450 3A4.
Topics: Animals; Carbamates; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Furans; Gene Expression; Gene Expression Regulation; HIV Protease Inhibitors; Humans; Intestine, Small; Ketoconazole; Liver; Male; Mice; Mice, Knockout; Mice, Transgenic; Microsomes, Liver; Models, Animal; Nelfinavir; Pregnane X Receptor; Pregnenolone Carbonitrile; Receptors, Steroid; Rifampin; Saquinavir; Sex Characteristics; Sulfonamides | 2008 |
Protothecosis as a cause of chronic diarrhoea in a dog.
Topics: Animals; Antifungal Agents; Colon; Diarrhea; Dog Diseases; Dogs; Fatal Outcome; Infections; Jejunum; Ketoconazole; Male; Prototheca; Rifampin | 2008 |
Inhibition of CYP3A4 expression by ketoconazole is mediated by the disruption of pregnane X receptor, steroid receptor coactivator-1, and hepatocyte nuclear factor 4alpha interaction.
Topics: Antifungal Agents; Base Sequence; Cell Line; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; DNA Primers; Gene Expression Regulation, Enzymologic; HeLa Cells; Hepatocyte Nuclear Factor 4; Histone Acetyltransferases; Humans; In Vitro Techniques; Ketoconazole; Ligands; Nuclear Receptor Coactivator 1; Pharmacogenetics; Pregnane X Receptor; Promoter Regions, Genetic; Protein Interaction Domains and Motifs; Receptors, Steroid; Recombinant Proteins; Rifampin; RNA Interference; Transcription Factors; Two-Hybrid System Techniques | 2009 |
CYP3A4 catalytic activity is induced in confluent Huh7 hepatoma cells.
Topics: Aflatoxin B1; Catalysis; Cell Line; Cell Line, Tumor; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Gene Expression; Humans; Ketoconazole; Microsomes, Liver; Midazolam; Rifampin; Testosterone; Transcription Factors | 2010 |
Metabolism and action of proteasome inhibitors in primary human hepatocytes.
Topics: Adolescent; Adult; Cells, Cultured; Cytochrome P-450 CYP3A Inhibitors; Female; Hepatocytes; Humans; Infant; Ketoconazole; Leupeptins; Male; Middle Aged; Nitric Oxide; Phenobarbital; Protease Inhibitors; Proteasome Inhibitors; Rifampin | 2010 |
Inhibitory effects of ketoconazole and rifampin on OAT1 and OATP1B1 transport activities: considerations on drug-drug interactions.
Topics: Animals; Antibiotics, Antitubercular; Antifungal Agents; Biological Transport; Drug Interactions; Imidazoles; Ketoconazole; Liver-Specific Organic Anion Transporter 1; Oocytes; Organic Anion Transport Protein 1; Organic Anion Transporters; Rifampin; Tetrazoles; Xenopus laevis | 2011 |
Influence of P-glycoprotein modulation on plasma concentrations and pharmacokinetics of orally administered prednisolone in dogs.
Topics: Administration, Oral; Analysis of Variance; Animals; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biopsy; Chromatography, Liquid; Dogs; Gene Expression Regulation; Ketoconazole; Prednisolone; Real-Time Polymerase Chain Reaction; Rifampin; Tandem Mass Spectrometry | 2012 |
The effect of CYP3A inhibitors and inducers on the pharmacokinetics of telaprevir in healthy volunteers.
Topics: Adult; Alkynes; Area Under Curve; Benzoxazines; Clinical Trials as Topic; Cyclopropanes; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Combinations; Drug Interactions; Enzyme Inhibitors; Female; Humans; Ketoconazole; Male; Middle Aged; Oligopeptides; Rifampin | 2013 |
Novel yeast-based strategy unveils antagonist binding regions on the nuclear xenobiotic receptor PXR.
Topics: Amino Acid Motifs; Amino Acid Substitution; Animals; Antifungal Agents; Binding Sites; Cell Line; Chlorocebus aethiops; Cloning, Molecular; Drug Resistance, Fungal; Humans; Ketoconazole; Molecular Docking Simulation; Mutagenesis; Oncogene Protein pp60(v-src); Pregnane X Receptor; Protein Binding; Receptors, Steroid; Recombinant Proteins; Rifampin; Saccharomyces cerevisiae; Transcriptional Activation; Two-Hybrid System Techniques; Xenobiotics | 2013 |
Use of rifabutin for the treatment of a latent tuberculosis infection in a patient after solid organ transplantation.
Topics: Adolescent; Antibiotics, Antitubercular; Drug Interactions; Drug Monitoring; Drug Substitution; Drug Therapy, Combination; Humans; Immunosuppressive Agents; Ketoconazole; Kidney Transplantation; Latent Tuberculosis; Liver Transplantation; Long QT Syndrome; Male; Rifabutin; Rifampin; Tacrolimus; Treatment Outcome | 2013 |
Effect of netupitant, a highly selective NK₁ receptor antagonist, on the pharmacokinetics of palonosetron and impact of the fixed dose combination of netupitant and palonosetron when coadministered with ketoconazole, rifampicin, and oral contraceptives.
Topics: Adolescent; Adult; Antiemetics; Area Under Curve; Contraceptives, Oral; Cross-Over Studies; Drug Interactions; Female; Humans; Isoquinolines; Ketoconazole; Middle Aged; Neurokinin-1 Receptor Antagonists; Palonosetron; Pyridines; Quinuclidines; Randomized Controlled Trials as Topic; Rifampin; Young Adult | 2013 |
Ritonavir and efavirenz significantly alter the metabolism of erlotinib--an observation in primary cultures of human hepatocytes that is relevant to HIV patients with cancer.
Topics: 14-alpha Demethylase Inhibitors; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Drug Interactions; Erlotinib Hydrochloride; Female; Half-Life; Hepatocytes; HIV Infections; HIV Protease Inhibitors; Humans; Ketoconazole; Male; Middle Aged; Neoplasms; Nucleic Acid Synthesis Inhibitors; Quinazolines; Rifampin; Ritonavir | 2013 |
Effects of ketoconazole and rifampicin on the pharmacokinetics of GLS4, a novel anti-hepatitis B virus compound, in dogs.
Topics: Administration, Oral; Animals; Antiviral Agents; Area Under Curve; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP3A; Dogs; Drug Interactions; Enzyme Induction; Enzyme Inhibitors; Humans; Ketoconazole; Male; Microsomes, Liver; Pyrimidines; Rifampin; Species Specificity; Tandem Mass Spectrometry; Thiazoles | 2013 |
Differential effects of Rifampin and Ketoconazole on the blood and liver concentration of atorvastatin in wild-type and Cyp3a and Oatp1a/b knockout mice.
Topics: Animals; Atorvastatin; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Female; HEK293 Cells; Heptanoic Acids; Humans; Ketoconazole; Liver; Mice; Mice, Knockout; Organic Anion Transport Protein 1; Pyrroles; Rifampin | 2014 |
Potential interactions between HIV drugs, ritonavir and efavirenz and anticancer drug, nilotinib--a study in primary cultures of human hepatocytes that is applicable to HIV patients with cancer.
Topics: Adult; Aged; Alkynes; Anti-HIV Agents; Antibiotics, Antitubercular; Antifungal Agents; Antineoplastic Agents; Area Under Curve; Benzoxazines; Cells, Cultured; Cyclopropanes; Drug Interactions; Female; Half-Life; Hepatocytes; Humans; Ketoconazole; Male; Middle Aged; Pyrimidines; Rifampin; Ritonavir; Young Adult | 2014 |
Physiologically based pharmacokinetic modeling for assessing the clinical drug-drug interaction of alisporivir.
Topics: Administration, Oral; Caco-2 Cells; Cyclosporine; Cytochrome P-450 CYP3A; Dose-Response Relationship, Drug; Drug Interactions; Humans; Ketoconazole; Models, Biological; Rifampin | 2014 |
Effects of rifampin and ketoconazole on pharmacokinetics of morinidazole in healthy chinese subjects.
Topics: Animals; Antifungal Agents; Candida glabrata; Candidiasis; Cell Line; Female; Fluconazole; Fungal Proteins; Humans; Immunoblotting; Ketoconazole; Lectins; Membrane Transport Proteins; Mice; Mice, Inbred BALB C; Nitroimidazoles; Open Reading Frames; Rifampin | 2014 |
Physiologically based pharmacokinetic modeling as a tool to predict drug interactions for antibody-drug conjugates.
Topics: Brentuximab Vedotin; Computer Simulation; Drug Interactions; Humans; Immunoconjugates; Ketoconazole; Midazolam; Models, Biological; Oligopeptides; Rifampin | 2015 |
Memory recuperative potential of rifampicin in aluminum chloride-induced dementia: role of pregnane X receptors.
Topics: Acetylcholinesterase; Aluminum Chloride; Aluminum Compounds; Amyloid; Animals; Brain; Chlorides; Cognition; Dementia; Disease Models, Animal; Female; Glutathione; Ketoconazole; Male; Motor Activity; Neutrophils; Nitrites; Nootropic Agents; Peroxidase; Pregnane X Receptor; Rats, Wistar; Receptors, Steroid; Rifampin; Thiobarbituric Acid Reactive Substances | 2015 |
Predicting drug-drug interactions involving multiple mechanisms using physiologically based pharmacokinetic modeling: a case study with ruxolitinib.
Topics: Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Digoxin; Drug Interactions; Erythromycin; Fasting; Fluconazole; Humans; Ketoconazole; Models, Biological; Nitriles; Prospective Studies; Pyrazoles; Pyrimidines; Retrospective Studies; Rifampin | 2015 |
Relative contributions of the major human CYP450 to the metabolism of icotinib and its implication in prediction of drug-drug interaction between icotinib and CYP3A4 inhibitors/inducers using physiologically based pharmacokinetic modeling.
Topics: Antineoplastic Agents; Area Under Curve; Computer Simulation; Crown Ethers; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Humans; Ketoconazole; Male; Microsomes, Liver; Models, Biological; Quinazolines; Rifampin | 2015 |
Clinical assessment of drug-drug interactions of tasimelteon, a novel dual melatonin receptor agonist.
Topics: Adolescent; Adult; Area Under Curve; Benzofurans; Cyclopropanes; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Female; Fluvoxamine; Half-Life; Humans; Ketoconazole; Male; Middle Aged; Molecular Structure; Receptors, Melatonin; Rifampin; Smoking; Young Adult | 2015 |
Human hepatocyte assessment of imatinib drug-drug interactions - complexities in clinical translation.
Topics: Adolescent; Adult; Aged; Alkynes; Anti-HIV Agents; Benzoxazines; Cyclopropanes; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Female; Hepatocytes; Humans; Imatinib Mesylate; Ketoconazole; Male; Middle Aged; Primary Cell Culture; Rifampin; Ritonavir; Young Adult | 2015 |
Physiologically-Based Pharmacokinetic Modeling of Macitentan: Prediction of Drug-Drug Interactions.
Topics: Adult; Cyclosporine; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Endothelin A Receptor Antagonists; Endothelin B Receptor Antagonists; Humans; Ketoconazole; Male; Models, Biological; Pyrimidines; Rifampin; Sildenafil Citrate; Sulfonamides; Warfarin | 2016 |
Impact on abiraterone pharmacokinetics and safety: Open-label drug-drug interaction studies with ketoconazole and rifampicin.
Topics: Abiraterone Acetate; Adolescent; Adult; Area Under Curve; Belgium; Biotransformation; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Half-Life; Healthy Volunteers; Humans; Ketoconazole; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Oxides; Rifampin; Sulfates; Young Adult | 2015 |
Application of Physiologically Based Pharmacokinetic Modeling to the Understanding of Bosutinib Pharmacokinetics: Prediction of Drug-Drug and Drug-Disease Interactions.
Topics: Administration, Oral; Aniline Compounds; Area Under Curve; Computer Simulation; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Humans; Ketoconazole; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Models, Biological; Nitriles; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-abl; Quinolines; Rifampin; src-Family Kinases; Treatment Outcome | 2017 |
Prediction of drug-drug interactions using physiologically-based pharmacokinetic models of CYP450 modulators included in Simcyp software.
Topics: Ciprofloxacin; Clarithromycin; Computer Simulation; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A Inhibitors; Cytochrome P-450 Enzyme Inducers; Drug Interactions; Fluconazole; Humans; Itraconazole; Ketoconazole; Models, Biological; Paroxetine; Quinidine; Rifampin; Software | 2018 |
Pharmacokinetic Evaluation of the Interactions of Amenamevir (ASP2151) with Ketoconazole, Rifampicin, Midazolam, and Warfarin in Healthy Adults.
Topics: Adolescent; Adult; Area Under Curve; Cross-Over Studies; Cytochrome P-450 CYP3A; Double-Blind Method; Drug Interactions; Enzyme Induction; Humans; Ketoconazole; Male; Metabolic Clearance Rate; Midazolam; Middle Aged; Oxadiazoles; Rifampin; Warfarin; Young Adult | 2017 |
A Physiologically Based Pharmacokinetic Modeling Approach to Predict Drug-Drug Interactions of Buprenorphine After Subcutaneous Administration of CAM2038 With Perpetrators of CYP3A4.
Topics: Administration, Cutaneous; Administration, Sublingual; Buprenorphine; Chemistry, Pharmaceutical; Clinical Trials, Phase I as Topic; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Humans; Ketoconazole; Rifampin | 2018 |
Simultaneous Physiologically Based Pharmacokinetic (PBPK) Modeling of Parent and Active Metabolites to Investigate Complex CYP3A4 Drug-Drug Interaction Potential: A Case Example of Midostaurin.
Topics: Adult; Biomarkers; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Female; Humans; Hydroxycholesterols; Ketoconazole; Male; Midazolam; Middle Aged; Models, Biological; Rifampin; Staurosporine; Young Adult | 2018 |
A human xenobiotic nuclear receptor contributes to nonresponsiveness of
Topics: Animals; Antibiotics, Antitubercular; ATP-Binding Cassette Transporters; Cells, Cultured; Drug Resistance, Bacterial; Gene Expression Regulation; Gene Transfer Techniques; Genes, Reporter; Host-Pathogen Interactions; Humans; Ketoconazole; Lung; Macrophages; Male; Mice, Inbred C57BL; Microbial Viability; Mycobacterium tuberculosis; Pregnane X Receptor; Recombinant Proteins; Rifampin; RNA Interference; Tuberculosis, Pulmonary | 2018 |
Application of Physiologically Based Pharmacokinetic Modeling in Understanding Bosutinib Drug-Drug Interactions: Importance of Intestinal P-Glycoprotein.
Topics: Administration, Oral; Aniline Compounds; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Availability; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Female; Humans; Intestinal Mucosa; Ketoconazole; Male; Nitriles; Quinolines; Rifampin | 2018 |
Development of a physiologically based pharmacokinetic model for mefloquine and its application alongside a clinical effectiveness model to select an optimal dose for prevention of malaria in young Caucasian children.
Topics: Adult; Age Factors; Antimalarials; Child; Child, Preschool; Drug Dosage Calculations; Drug Interactions; Female; Humans; Infant; Ketoconazole; Malaria; Mefloquine; Middle Aged; Models, Biological; Rifampin; Treatment Outcome; White People; Young Adult | 2019 |
Physiologically Based Pharmacokinetic Modeling Suggests Limited Drug-Drug Interaction for Fesoterodine When Coadministered With Mirabegron.
Topics: Acetanilides; Adult; Benzhydryl Compounds; Cresols; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Female; Humans; Ketoconazole; Male; Middle Aged; Rifampin; Thiazoles; Urinary Bladder, Overactive | 2019 |
Drug-drug interaction (DDI) assessments of ruxolitinib, a dual substrate of CYP3A4 and CYP2C9, using a verified physiologically based pharmacokinetic (PBPK) model to support regulatory submissions.
Topics: Administration, Oral; Caco-2 Cells; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP3A; Drug Interactions; Erythromycin; Humans; Ketoconazole; Models, Biological; Nitriles; Pyrazoles; Pyrimidines; Rifampin | 2019 |
Changes in Bile Acid Concentrations after Administration of Ketoconazole or Rifampicin to Chimeric Mice with Humanized Liver.
Topics: Alanine Transaminase; Alkaline Phosphatase; Animals; Aspartate Aminotransferases; Bile Acids and Salts; Chemical and Drug Induced Liver Injury; Cholestasis; Humans; Ketoconazole; Liver; Male; Mice; Rifampin | 2019 |
Predicting Clinical Effects of CYP3A4 Modulators on Abemaciclib and Active Metabolites Exposure Using Physiologically Based Pharmacokinetic Modeling.
Topics: Administration, Oral; Adult; Aged; Alkynes; Aminopyridines; Area Under Curve; Benzimidazoles; Benzoxazines; Bosentan; Clarithromycin; Computer Simulation; Cyclin-Dependent Kinases; Cyclopropanes; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Diltiazem; Drug Interactions; Female; Healthy Volunteers; Humans; Itraconazole; Ketoconazole; Male; Middle Aged; Modafinil; Models, Biological; Rifampin; Verapamil | 2020 |
A Translational Physiologically Based Pharmacokinetics/Pharmacodynamics Framework of Target-Mediated Disposition, Target Inhibition and Drug-Drug Interactions of Bortezomib.
Topics: Animals; Antineoplastic Agents; Bortezomib; Drug Interactions; Female; Humans; Ketoconazole; Macaca fascicularis; Male; Models, Biological; Rifampin | 2020 |
Physiologically based pharmacokinetic modeling and simulation to predict drug-drug interactions of ivosidenib with CYP3A perpetrators in patients with acute myeloid leukemia.
Topics: Administration, Oral; Antineoplastic Agents; Area Under Curve; Computer Simulation; Cytochrome P-450 CYP3A; Cytochrome P-450 CYP3A Inducers; Cytochrome P-450 CYP3A Inhibitors; Drug Interactions; Female; Fluconazole; Glycine; Healthy Volunteers; Humans; Itraconazole; Ketoconazole; Leukemia, Myeloid, Acute; Male; Microsomes, Liver; Models, Biological; Pyridines; Rifampin | 2020 |
Physiologically Based Pharmacokinetic Model-Informed Drug Development for Polatuzumab Vedotin: Label for Drug-Drug Interactions Without Dedicated Clinical Trials.
Topics: Antibodies, Monoclonal; Brentuximab Vedotin; Computer Simulation; Cytochrome P-450 CYP3A; Drug Development; Drug Interactions; Drug Labeling; Humans; Immunoconjugates; Ketoconazole; Midazolam; Models, Biological; Oligopeptides; Rifampin | 2020 |
High frequency of azole resistant Candida spp. colonization among presumptive multidrug resistant tuberculosis (MDR-TB) patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antifungal Agents; Antitubercular Agents; Candida; Candidiasis; Child; Drug Interactions; Drug Resistance, Multiple, Fungal; Female; Fluconazole; Humans; Itraconazole; Ketoconazole; Male; Microbial Sensitivity Tests; Middle Aged; Rifampin; Species Specificity; Tuberculosis, Multidrug-Resistant; Young Adult | 2020 |